Literature DB >> 1558796

Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer.

Y Maehara1, K Sugimachi, M Akagi, T Kakegawa, H Shimazu, M Tomita.   

Abstract

We studied the effect of early postoperative chemotherapy, including 5-fluorouracil (5-FU) for 5 days for patients with gastric cancer following noncurative resection. The study was prospectively randomised and controlled, and 162 (87.1%) of 186 were eligible candidates for statistical assessment. Patients randomised to group A received therapy that is used widely to treat patients with gastric cancer in Japan; mitomycin C (MMC), OK-432, UFT and PSK. Patients randomised to group B received the same drugs given to group A plus 5-FU bolus injections for 5 days, beginning on postoperative day 2. There were no differences in prognostic factors and doses of the drugs prescribed, except for 5-FU. There was no difference in the toxicity rate between the groups. Generalised Wilcoxon test revealed a P value of 0.169, and the 50% survival rate improved 1.4-fold in patients with gastric cancer treated with early postoperative chemotherapy of MMC, OK-432 plus 5-FU injection.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1558796      PMCID： PMC1977594          DOI： 10.1038/bjc.1992.84

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  19 in total

1.  Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma.

Authors:  Y Maehara; A Watanabe; Y Kakeji; H Baba; S Kohnoe; K Sugimachi
Journal:  Am J Surg       Date:  1990-09       Impact factor: 2.565

2.  Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection.

Authors:  Y Maehara; S Moriguchi; Y Sakaguchi; Y Emi; S Kohnoe; S Tsujitani; K Sugimachi
Journal:  J Surg Oncol       Date:  1990-11       Impact factor: 3.454

3.  Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.

Authors:  P Seifert; L H Baker; M L Reed; V K Vaitkevicius
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

4.  Strategy for lymphadenectomy of gastric cancer.

Authors:  T Boku; Y Nakane; T Okusa; N Hirozane; N Imabayashi; K Hioki; M Yamamoto
Journal:  Surgery       Date:  1989-05       Impact factor: 3.982

Review 5.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

Review 6.  Chemotherapy in gastrointestinal malignancies.

Authors:  D G Haller
Journal:  Semin Oncol       Date:  1988-06       Impact factor: 4.929

7.  Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.

Authors:  R J Fraile; L H Baker; T R Buroker; J Horwitz; V K Vaitkevicius
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

8.  Effect of surgical removal on the growth and kinetics of residual tumor.

Authors:  N Gunduz; B Fisher; E A Saffer
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

9.  An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group.

Authors:  J W Fielding; S L Fagg; B G Jones; D Ellis; M S Hockey; A Minawa; V S Brookes; J L Craven; M C Mason; A Timothy; J A Waterhouse; P F Wrigley
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

10.  Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).

Authors:  P F Engstrom; P T Lavin; H O Douglass; K W Brunner
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860
View more
  11 in total

1.  Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.

Authors:  Toshiro Okuyama; Daisuke Korenaga; Ai Edagawa; Shinji Itoh; Eiji Oki; Hirofumi Kawanaka; Yasuharu Ikeda; Yoshihiro Kakeji; Masahiro Tateishi; Shunichi Tsujitani; Kenji Takenaka; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-01-27       Impact factor: 2.549

2.  Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases.

Authors:  Souya Nunobe; Naoki Hiki; Shigekazu Ohyama; Tetsu Fukunaga; Yasuyuki Seto; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2007-12-01       Impact factor: 3.445

3.  Surgical treatment and prognosis of gastric cancer in 2,613 patients.

Authors:  Xiang-Fu Zhang; Chang-Ming Huang; Hui-Shan Lu; Xing-Yuan Wu; Chuang Wang; Guo-Xian Guang; Jian-Zhong Zhang; Chao-Hui Zheng
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Surgical indications for gastrectomy combined with distal or partial pancreatectomy in patients with gastric cancer.

Authors:  Yasuo Sakamoto; Yoshihisa Sakaguchi; Masahiko Sugiyama; Kazuhito Minami; Yasushi Toh; Takeshi Okamura
Journal:  World J Surg       Date:  2012-10       Impact factor: 3.352

5.  Long-term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis: report of a case.

Authors:  S Otani; M Maeta; A Oka; Y Hirooka; S Tsujitani; M Ikeguchi; R Hamazoe; N Kaibara
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 6.  Trametes versicolor mushroom immune therapy in breast cancer.

Authors:  Leanna J Standish; Cynthia A Wenner; Erin S Sweet; Carly Bridge; Ana Nelson; Mark Martzen; Jeffrey Novack; Carolyn Torkelson
Journal:  J Soc Integr Oncol       Date:  2008

7.  Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.

Authors:  Y Maehara; S Inutsuka; H Takeuchi; H Baba; H Kusumoto; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination.

Authors:  Y Maehara; H Takeuchi; T Oshiro; I Takahashi; S Inutsuka; H Baba; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Factors affecting aminolaevulinic acid-induced generation of protoporphyrin IX.

Authors:  L Wyld; J L Burn; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.

Authors:  E Oki; Y Sakaguchi; Y Toh; S Oda; Y Maehara; N Yamamoto; K Sugimachi
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.